Innocan Pharma Reports Q1 Revenue Up 29.7% Sequentially, Defers US IPO
Summary
Innocan Pharma reported Q1 2026 revenues of $6.47 million, a 29.7% sequential increase from Q4 2025. However, year-over-year revenue declined by 17.07%, and the operating loss widened significantly by 261.1% to $0.786 million. The company also announced it is deferring its proposed US initial public offering, a change from the F-1/A filings in early April that outlined plans for an IPO. This strategic shift impacts the company's funding and growth trajectory.
At the time of this announcement, INNPF was trading at $2.50 on OTC in the Life Sciences sector, with a market capitalization of approximately $11.2M. The 52-week trading range was $2.50 to $82.59. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.